Evaluation of urine drug screen falsification of results among patients with opioid use disorder receiving treatment in a telehealth model of care.

Introduction: As telehealth models for treatment of opioid use disorder (OUD) are expanding, the field does not know the reliability of urine drug screening (UDS) in this setting. The objective of this study is to determine the rate of falsification of UDS testing among patients with OUD in active treatment with buprenorphine via a telehealth provider.
Methods: This is a prospective cohort study of 899 randomly selected eligible patients, of which 392 participated in the final cohort that the study team used for analysis. The study mailed patients a UDS cup and asked them to return the sample by mail. After the UDS sample was received, a buccal swab was mailed, and the study asked patients to schedule a virtual meeting in which consent was sought and an observed buccal swab was obtained. We evaluated urine for evidence of falsification, and used buccal swabs to genetically match individuals to urine samples.
Results: After exclusion criteria, 395 (52.3 %) of 755 patients who received a UDS kit returned it for analysis prior to knowledge of the study. Of that, 392 samples had sufficient quantity for testing. We determined 383 (97.7 %) to be human urine containing buprenorphine without indication of exogenous buprenorphine addition and with evidence of compliance. A total of 374 patients received a buccal swab kit and 139 (37.2 %) attended the consent/observed buccal swab session. One hundred and thirty-two patients consented and completed the swab under video observation, and 120 successfully sent the swab back to the external laboratory. Of the 120 buccal swabs received, 109 (90.8 %) were a genetic match, 10 (8.3 %) were indeterminate, and 1 (0.8 %) was a genetic mismatch.
Conclusions: This study of patients treated by a telehealth OUD provider demonstrated a low rate of urine test falsification.
Competing Interests: Declaration of competing interest Dr. Weiner is an advisory committee member of Vertex Pharmaceuticals, Inc. and Cessation Therapeutics, Inc. Dr. Clear and Dr. Weiner have ownership interest in Bicycle Health, Inc. Other authors report no relevant conflicts of interest.
(Copyright © 2023 Elsevier Inc. All rights reserved.)